MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence
Radhika Mathur(University of California, San Francisco), J Costello(University of California, San Francisco), Kevin Petrecca(McGill University Health Centre), Nancy Ann Oberheim-Bush(University of California, San Francisco), Annette M. Molinaro(University of California, San Francisco), Jennifer Clarke(Cornell University), Saumya Bollam(University of California, San Francisco), Matthew Grimmer(Sequenom (United States)), Michael Zhang(Stanford Medicine), Yalan Zhang(University of California, San Francisco), Chibo Hong(Universidad Católica de Santa Fe), Mitchel S. Berger(University of California, San Francisco), Susan M. Chang(University of San Francisco), Joanna J. Phillips(University of California, San Francisco)
Cited by 96
Related Papers
The NIH Roadmap Epigenomics Mapping Consortium
|Nature Biotechnology|2010|2k
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k
Impact of Intraoperative Stimulation Brain Mapping on Glioma Surgery Outcome: A Meta-Analysis
|Journal of Clinical Oncology|2012|1k